On October 6, 2025, Humacyte, Inc. announced a direct offering of 28,436,018 shares of common stock and warrants at $2.11 each, with expected closing on October 8, 2025. This event involves a significant capital raise with warrants exercisable in 180 days and expiring April 7, 2031.